| abstract |
The present invention relates to an oxime derivative represented by the following general formula (I), a process for producing the same, a pharmaceutical composition containing the same, and a method of using the same. In particular, the oxime derivatives according to the present invention act as GPR119 agonists which promote the secretion of GLP-1 and also increase insulin secretion for the treatment of type 2 diabetes, complications of diabetes, obesity, dyslipidemia or osteoporosis . [Chemical Formula 1] Wherein R A, R B, n, Ar, A, B, R 1 and R 2 are as defined in the specification. |